NCT06210633 Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke
| NCT ID | NCT06210633 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongming Qiu |
| Condition | Acute Ischemic Stroke (AIS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-01-20 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-01-20 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Since 2015, many randomized trials have shown that endovascular thrombectomy improve functional outcomes in acute ischemic stroke patients with large vessel occlusion. Recently, five randomized controlled trials (ANGEL-ASPECT \[Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core\], LASTE \[LArge Stroke Therapy Evaluation\], RESCUE-Japan LIMIT \[The Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Large Ischemic Core Trial\], SELECT 2 \[Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke\], and TENSION \[The Efficacy and Safety of Thrombectomy in Stroke with extended lesion and extended time window\]) demonstrated the efficacy and safety of thrombectomy for large infarct patients (defined as Alberta Stroke Program Early Computed Tomography Score \[ASPECTS\] ≥3 or infarct core \<100ml). Patients with extra-large infarct core (ASPECTS score of 2 or less) were excluded from these trials. Therefore, the efficacy of endovascular thrombectomy in patients with extra-large ischemic burden has not been well studied. The XL STROKE registry is aiming to investigate the clinical outcomes and safety of mechanical thrombectomy in acute extra-large ischemic stroke.
Eligibility Criteria
Inclusion Criteria: Clinical inclusion criteria 1. Age ≥18 years; 2. Presenting with acute ischemic stroke within 24 hours of time from last known well; 3. The patient or patient's representative signs a written informed consent form before enrollment. Neuroimaging inclusion criteria 1. Occlusion of internal carotid artery, or the middle cerebral artery M1 or M2 segments confirmed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography; 2. The baseline ASPECTS is 0 to 2 based on NCCT or diffusion weighted imaging, or cerebral extra-large ischemic core volume ≥85ml (defined as relative cerebral blood flow \<30% on CT perfusion or an apparent diffusion coefficient \<620×10\^-6 mm2/s on MRI). Exclusion criteria 1. CT or MRI evidence of acute intracranial hemorrhage; 2. Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging; 3. Females who are pregnant, or those of childbearing, potential with positive urine or serum beta Human Chorionic Gonadotropin test; 4. Previous bleeding disorders, severe heart, liver or kidney disease, or sepsis; 5. Any terminal illness with life expectancy less than 6 months; 6. Participation in other clinical treatment trials.
Contact & Investigator
Guangxiong Yuan
PRINCIPAL INVESTIGATOR
Xiangtan Central Hospital
Frequently Asked Questions
Who can join the NCT06210633 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke (AIS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06210633 currently recruiting?
Yes, NCT06210633 is actively recruiting participants. Contact the research team at qiuzhongmingdoctor@163.com for enrollment information.
Where is the NCT06210633 trial being conducted?
This trial is being conducted at Xiangtan, China.
Who is sponsoring the NCT06210633 clinical trial?
NCT06210633 is sponsored by Zhongming Qiu. The principal investigator is Guangxiong Yuan at Xiangtan Central Hospital. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.